Cyclic diacyl thioureas enhance activity of corrector Lumacaftor on F508del-CFTR

ChemMedChem. 2024 Feb 16;19(4):e202300391. doi: 10.1002/cmdc.202300391. Epub 2024 Jan 16.

Abstract

Cystic fibrosis is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. In the search of novel series of CFTR modulators, a library of mono and diacyl thioureas were prepared by sequential synthesis. When tested alone, the obtained compounds 5 and 6 poorly affected F508del-CFTR conductance but, in combination with Lumacaftor, selected derivatives showed the ability to increase the activity of the approved modulator. Analogue 6 i displayed the most marked enhancing effect and acylthioureas 6 d and 6 f were also able to improve efficacy of Lumacaftor. All compounds proved to be non-cytotoxic against different cancer cell lines. Good pharmacokinetic properties were predicted for derivatives 5 and 6, thus supporting the value of these compounds for the development of novel modulators potentially useful for cystic fibrosis.

Keywords: Acylthioureas; CFTR modulator; Cystic fibrosis; cytotoxic activity; tumor cell lines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopyridines / pharmacology
  • Benzodioxoles / pharmacology
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics
  • Cystic Fibrosis* / drug therapy
  • Cystic Fibrosis* / genetics
  • Humans
  • Mutation

Substances

  • Cystic Fibrosis Transmembrane Conductance Regulator
  • lumacaftor
  • Aminopyridines
  • Benzodioxoles
  • CFTR protein, human